Want to join the conversation?
In 1Q16, $VRTX plans to commence a clinical trial for KALYDECO (ivacaftor) in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. $VRTX has submitted a supplemental New Drug Application, sNDA, for KALYDECO and a target review date for the sNDA is set for Feb. 6, 2016.
$AGIO plunge 15%.. what's happening... is this going for a toss !
Does anyone feel $SBUX CEO Schultz stepping down could prove a disaster for the company?
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.